Clinical Trials Directory

Trials / Terminated

TerminatedNCT05153330

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
55 (actual)
Sponsor
Biomea Fusion Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

Detailed description

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) with mixed lineage leukemia 1-rearranged (KMT2A/ MLL1r), nucleophosmin 1 (NPM1), diffuse large b-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic lymphoma (CLL)/ small lymphocytic lymphoma (SLL).

Conditions

Interventions

TypeNameDescription
DRUGBMF-219BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.

Timeline

Start date
2022-01-24
Primary completion
2025-02-13
Completion
2025-05-02
First posted
2021-12-10
Last updated
2025-07-03

Locations

41 sites across 5 countries: United States, Greece, Italy, Netherlands, Spain

Regulatory

Source: ClinicalTrials.gov record NCT05153330. Inclusion in this directory is not an endorsement.